Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030183 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
A Phase 2 study, sponsored by Ra Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03030183: Completed Phase 2 study, sponsored by Ra Pharmaceuticals.
NCT03030183 is a Phase 2 study that has completed, run by Ra Pharmaceuticals. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030183, a Phase 2 study, has completed, sponsored by Ra Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.
Primary Outcome
Change-from-baseline through Week 12 in serum lactate dehydrogenase (LDH) levels
Interventions
- DRUG Zilucoplan (RA101495)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 2 |
What the finished NCT03030183 record still lists
NCT03030183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Zilucoplan (RA101495) is the first listed.
NCT03030183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03030183 about?
NCT03030183 is a clinical study titled "Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab". The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.
What is the current status of trial NCT03030183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-04-17. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT03030183?
The interventions under investigation include: Zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT03030183?
This trial is sponsored by Ra Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03030183's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI